KLOW vs GLOW: What the Research Shows
KLOW and GLOW side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider KLOW if…
- you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.[13]
Consider GLOW if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
What they have in common
Spec comparison
Showing 3 of 12 fields where the two differ. Also called, Category, FDA status, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength, Typical study doses are the same or both unknown.
| Field | KLOW | GLOW |
|---|---|---|
| Class | Four-peptide blend | Three-peptide blend |
| Also called | — | — |
| Category | Healing & recovery | Healing & recovery |
| FDA status | Not FDA approved · unstudied blend | Not FDA approved · unstudied blend |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. |
| Anti-doping detection |
|
|
| Half-life | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 |
| Evidence strength | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 |
| Human studies we summarised | 15 human (9 randomized or controlled) of 65 summarised, across ingredients | 15 human (9 randomized or controlled) of 56 summarised, across ingredients |
| Typical study doses |
|
|
| Vial sizes sold | 80 mg | 50 mg, 70 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
The whole difference is one ingredient: KPV
GLOW and KLOW share GHK-Cu, BPC-157 and TB-500; what KLOW adds is KPV, and KPV is the least-studied of the four in people.[14]
The KPV literature is mouse colitis and peritonitis experiments, plus cell and skin-sample work; a mouse study found oral KPV lowered colitis incidence.[15]
Even the delivery question is open: KPV in a skin-permeation test did not cross human skin by simple diffusion, an ex vivo result that says nothing about injection.[16]
For the three components the two blends have in common, the one experiment that combined two of them found no extra benefit over either one alone, in rat Achilles tendons.[17]
The 'glow' in the name points at skin, where GHK-Cu is the only component with human trials, and those are small topical studies.[18]
What the extra ingredient changes in practice
KPV has no published stability guidance for a reconstituted vial; the only study is a stress test that identified a breakdown product under acid, alkali and peroxide.[19]
Neither blend escapes the anti-doping list, because TB-500 appears in both.[1]
FDA's regulatory page treats TB-500 as having no human exposure data, which applies equally to both blends.[14]
Because KLOW carries a fourth peptide, any adverse event cannot be pinned on a single ingredient; BPC-157's own pilot of intravenous infusion in two people reported no side effects, but that is far too small to compare blends.[20]
Common questions
What is the difference between KLOW and GLOW peptide?
KLOW adds KPV to the GHK-Cu, BPC-157 and TB-500 base that GLOW has; FDA reports no human exposure data for KPV.[14]
Is KLOW stronger than GLOW?
Nothing in the literature measures strength of either blend; the nearest experiment found two of the shared ingredients together gave no added benefit over one in rats.[17]
Which is better for skin, KLOW or GLOW?
The only skin evidence among the ingredients is for GHK-Cu, which both blends contain; KPV's skin data are cell and ex vivo skin tests.[18]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 3Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 4Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 5Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 7Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 8A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 9Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 10Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 11PubMed search: (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab])) AND (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 13Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 14Official web pageOfficial web page · web page
- 15PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 16Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
- 17Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 18Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
- 19Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
- 20Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
Found an error? Report a correction.